Abstract:
Number one Pharmaceutical Company in France and in Europe, number
three worldwide sanofi-aventis has been positioned as a key player in the
healthcare. The Group was set up more than 30 years ago.
Their business consists of discovering, developing and providing physicians
and patients throughout the world whit innovative, effective, well-tolerated and
high-quality treatments, whilst maintaining the economic performance levels
that will permit them to continue this undertaking. As a global industry leader Sanofi-aventis seek to conquer and prevent
disease by bringing to market innovative pharmaceuticals, vaccines,
therapeutic proteins and diagnostics. Aventis pharma was created as a part of
the 1999 business combination of Hoechst and Rhone-Poulenc to form
Aventis SA, one of the world's leading life sciences companies. Aventis
Pharma concentrates its efforts on strategic brands that meet growing patient
needs and contribute to a long-term sales growth. With 2001 sales of 15.168
billion euro (excluding sales of diagnostics), Aventis Pharma contributes
three-quarters of the life sciences sales of Aventis SA. The Aventis Pharma
prescription drug business is investing about 2.98 billion euro a year in Drug
Innovation and Approval, one of the industry's largest R&D budgets.
Description:
This thesis submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy (B.Pharm) in East West University, Dhaka, Bangladesh.
